06.06.2011Positive Outcome for Algeta in Pivotal Alpharadin Study

Positive outcome of Interim Analysis of pivotal Alpharadin study: Primary endpoint met in Phase III ALSYMPCA study

Press Release

15.04.2011Conatus CTS-1027

Conatus Pharmaceuticals Inc. announces interim results from a clinical trial with CTS-1027

Press Release

16.02.2011Versartis Completes $21 Million Series B Financing

Completion of Versartis Series B Financing

Press Release

24.11.2010Final close of Advent Life Sciences

Advent Venture Partners today announced the final close of a $120M (£75M) venture capital fund, to be called Advent Life Sciences

Press Release

04.11.2010Algeta wins Scrip Award for Biotechnology Company of the Year

Scrip's Biotech Company of the Year award seeks to acknowledge the vital importance to the industry of biotechnology’s cutting-edge science and entrepreneurial spirit.  This year, from a strong field, the judges chose Algeta as the winner.

In The News

02.11.2010Avila Presents New Data on its Novel, Orally-Available Targeted Covalent Drug, AVL-192

Avila Therapeutics™, Inc., a biotechnology company developing novel targeted covalent drugs, presented results today of preclinical studies that demonstrate its orally-available targeted covalent drug candidate, AVL-192, achieves superior potency against drug-resistant mutations of the Hepatitis C Virus (HCV).

Press Release